Published in Pediatr Infect Dis J on March 01, 2015
Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA (2009) 3.32
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis (2007) 2.45
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Introducing a new group B meningococcus vaccine. BMJ (2014) 2.13
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol (2010) 2.11
Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med (2010) 1.99
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic. PLoS One (2008) 1.84
Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic. Math Biosci (2007) 1.82
Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine (2009) 1.79
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis (2003) 1.76
Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods (2004) 1.74
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine (2002) 1.68
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis (2013) 1.66
Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals. Neurology (2012) 1.65
A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS One (2007) 1.64
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine (2003) 1.60
Understanding influenza transmission, immunity and pandemic threats. Influenza Other Respir Viruses (2009) 1.60
Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin Diagn Lab Immunol (2004) 1.59
Added value of PCR-testing for confirmation of invasive meningococcal disease in England. J Infect (2013) 1.58
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J (2006) 1.57
Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery. Arch Dis Child (2011) 1.56
Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine (2012) 1.54
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine (2008) 1.52
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine (2013) 1.49
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine (2009) 1.44
A prospective study of etiology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis (2008) 1.44
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine (2008) 1.43
Molecular surveillance of true nontypeable Haemophilus influenzae: an evaluation of PCR screening assays. PLoS One (2012) 1.42
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40
Australia's contribution to global immunisation. Aust N Z J Public Health (2012) 1.39
Comparison of three methods for ascertainment of contact information relevant to respiratory pathogen transmission in encounter networks. BMC Infect Dis (2010) 1.38
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines (2011) 1.35
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis (2002) 1.33
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis (2007) 1.30
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med (2008) 1.30
Influenza: accounting for prior immunity. Science (2009) 1.28
Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS One (2008) 1.26
Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J (2005) 1.24
Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso. J Infect Dis (2007) 1.23
Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol (2004) 1.22
Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther (2011) 1.20
Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. PLoS Pathog (2013) 1.20
Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis (2007) 1.20
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine (2012) 1.19
Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol (2008) 1.19
Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol Microbiol (2004) 1.19
Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol (2011) 1.18
Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One (2011) 1.16
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun (2006) 1.15
Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC Infect Dis (2010) 1.14
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis (2013) 1.13
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog (2012) 1.10
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol (2008) 1.10
Haemophilus influenzae type b epiglottitis. Article gives timely lesson. BMJ (2003) 1.09
Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol (2010) 1.09
Neisseria lactamica protects against experimental meningococcal infection. Infect Immun (2002) 1.09
Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis (2009) 1.08
Improving influenza vaccination coverage in pregnancy in Melbourne 2010-2011. Aust N Z J Obstet Gynaecol (2012) 1.07
Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics (2011) 1.07
Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis (2011) 1.07
Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case-Control Study. Pediatr Infect Dis J (2011) 1.07
Nasopharyngeal carriage of Haemophilus haemolyticus in otitis-prone and healthy children. J Clin Microbiol (2010) 1.07
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vaccine Immunol (2009) 1.06
Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine (2003) 1.05
Immunity to tetanus and diphtheria in the UK in 2009. Vaccine (2012) 1.05
Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One (2013) 1.04
Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis (2011) 1.04
Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea. Vaccine (2009) 1.04
Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol (2006) 1.02
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine (2006) 1.02
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J (2012) 1.02
Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol (2009) 1.02
Acute emergence and reversion of influenza A virus quasispecies within CD8+ T cell antigenic peptides. Nat Commun (2013) 1.00
Making sense of perceptions of risk of diseases and vaccinations: a qualitative study combining models of health beliefs, decision-making and risk perception. BMC Public Health (2011) 1.00
Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One (2012) 1.00
Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm (2012) 1.00
Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis (2016) 1.00
Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA (2005) 0.99
The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell Q Rep (2004) 0.99
Neutrophil extracellular traps and bacterial biofilms in middle ear effusion of children with recurrent acute otitis media--a potential treatment target. PLoS One (2013) 0.99
Sequence conservation of pilus subunits in Neisseria meningitidis. Vaccine (2010) 0.98
Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines (2004) 0.98
Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations. J Allergy Clin Immunol (2009) 0.98